Lutetium Lu 177 dotatate

177Lu-dotatate showed activity and met progression-free survival (PFS) end point in surgery- or radiation-refractory grade 2/3 meningioma patients, with median PFS of 11.5 months and 2-year PFS rate of 26.7%. Median overall survival (OS) was 27.8 months, with 1-year OS rate of 88.9% and 2-year OS rate of 63.8%. Best response was stable disease. 177Lu-dotatate binds to somatostatin receptor 2 (SSTR2) expressed in 80%-100% of meningiomas, offering targeted radiation for refractory cases.

The incidence of neuroendocrine tumors (NETs) is rising in the US, with well-differentiated grade 3 NETs being a recent classification. Standard treatments for advanced NETs include somatostatin analogues, targeted therapy, and chemotherapy. The NETTER-1 trial showed that 177Lu-dotatate significantly improved progression-free survival (PFS) in midgut NETs, leading to FDA approval. NETTER-2, focusing on high grade 2 and grade 3 gastroenteropancreatic NETs, also demonstrated improved PFS with 177Lu-dotatate but no significant difference in quality of life (QOL) or overall survival (OS). The risk of myelodysplastic syndrome (MDS) and lack of QOL improvement suggest caution in using 177Lu-dotatate as a first-line therapy for all NET patients. Long-term data on OS, QOL, and safety are needed to determine its optimal use.

A phase 2 trial showed ¹⁷⁷Lu-Dotatate achieved a 6-month progression-free survival of 77.8% in refractory meningioma patients, surpassing the historical benchmark of 26%. Median PFS was 11.5 months, and median overall survival was 27.8 months. Common AEs included fatigue, lymphocyte count decrease, anemia, and nausea.

A phase 2 trial presented at the 2024 ASTRO Annual Meeting showed ¹⁷⁷Lu-Dotatate (Lutathera) achieved a median progression-free survival (PFS) of 11.5 months and a 2-year PFS rate of 26.7% in patients with refractory grade II/III meningioma. The median overall survival (OS) was 27.8 months, with a 1-year OS rate of 88.9% and a 2-year OS rate of 63.8%. The best response was stable disease, and ¹⁷⁷Lu-Dotatate was well-tolerated, supporting its use as a therapeutic option for limited alternative therapies.

Nicole M. Maughan, PhD, receives $100,000 SNMMI Mars Shot Fund award for establishing a centralized dosimetry process with peripheral SPECT/CT image acquisition in radiopharmaceutical therapy, aiming to improve personalized treatment in community practices.

A Phase II clinical trial with ¹⁷⁷Lu-Dotatate showed 78% progression-free survival at six months and 88.9% overall survival at one year in refractory meningioma patients, surpassing historical benchmarks, suggesting radiopharmaceuticals as a promising therapeutic option.

Radiopharmaceutical therapy ¹⁷⁷Lu-Dotatate shows promise for refractory meningioma, with 78% of patients progression-free at 6 months, surpassing prior benchmarks. The trial, led by Dr. Kenneth W. Merrell, suggests radiopharmaceuticals could be a safe and effective treatment option for aggressive meningiomas.

A phase II study using ¹⁷⁷Lu-Dotatate radiopharmaceutical therapy showed 78% of refractory meningioma patients were progression-free after six months, surpassing prior benchmarks. The trial, led by Dr. Kenneth W. Merrell and Dr. Geoffrey B. Johnson, suggests radiopharmaceuticals could be a promising treatment for this aggressive brain tumor.

Radiopharmaceutical therapy ¹⁷⁷Lu-Dotatate shows promise for refractory meningioma, with 78% of patients progression-free after six months in a phase II study, surpassing prior benchmarks. The therapy, presented at the ASTRO Annual Meeting, offers a safe and effective option for patients with limited alternative treatments.